At the ASCO 2026 Annual Meeting (May 29‑June 2), AstraZeneca will showcase more than 85 abstracts covering ten approved drugs and 13 pipeline candidates. Highlights include a new combination of Durvalumab and Tremelimumab (with or without Lenvatinib) for early‑stage liver cancer, and a first‑line antibody‑drug conjugate, Datopotamab‑deruxtecan, for triple‑negative breast cancer patients who can’t receive PD‑1/PD‑L1 blockers. The company also reports long‑term survival data for Durvalumab plus BCG in high‑risk bladder cancer, and an exploratory analysis of Trastuzumab‑deruxtecan with Pertuzumab in HER2‑positive metastatic breast cancer. In rare‑disease news, AstraZeneca’s Alexion unit will present Phase III results for anselimamab, a first‑in‑class anti‑amyloid antibody aimed at light‑chain amyloidosis, with promising outcomes for both kappa and lambda subtypes. Early‑phase breakthroughs include Puxi‑Sam, a B7‑H4‑targeted ADC that just earned FDA Breakthrough Therapy status, a PRMT5 inhibitor (AZD3470) for relapsed Hodgkin lymphoma, and NT‑175, a T‑cell receptor therapy for TP53‑mutated pancreatic cancer. Executives emphasized that these data illustrate AstraZeneca’s strategy of moving immunotherapies earlier in the disease course and expanding innovative options for patients, potentially reshaping cancer care and rare‑disease treatment.
Read more